Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Certifies Asuragen and DeCode as BeadChip Service Providers

This article has been updated from a previous version, which incorrectly identified Asuragen as an ABI subsidiary. The details of ABI's acquisition of Ambion have also been corrected. 
NEW YORK (GenomeWeb News) — Illumina today said it has certified Asuragen as a gene expression profiling services provider for its Human-6 Expression BeadChip.
Illumina has also certified DeCode Genetics to use its Infinium BeadChip genotyping platform.
Asuragen, which specializes in RNA, microRNA, and gene-expression and array products and services, will use the Human-6 BeadChip for profiling services to support clinical research studies, pharmacogenomics, and biomarker discovery.
The company is a spin-off of Ambion's diagnostics and services division that was created in 2006 when ABI purchased Ambion’s research products division for $273 million in cash. 
For Decode, to become a certified service provider for Illumina’s Infinium tool, the company passed a two-phase process that included data generation and data certification, and underwent on-site audits of processes and facilities.
DeCode will use the BeadChip platform in conjunction with its Disease Miner software and other disease-related IP to develop DNA-based diagnostics and to offer expanded contract genotyping services to its customers.
DeCode’s genotyping facility is located in its headquarters in Reykjavik, Iceland.
DeCode and Illumina last May signed an agreement to develop and market molecular diagnostics for type II diabetes, breast cancer and heart attack.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.